Day: October 11, 2024

Additive Manufacturing Market to Register CAGR of 20.8%, Attributed to Growing Demand for Prototype Applications from Different Industries

Written by Customer Service on October 11, 2024. Posted in Mergers And Acquisitions.

Westford, USA, Oct. 11, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Global Additive Manufacturing Market will reach a value of USD 91.59 Billion by 2031, with a CAGR of 20.8% during the forecast period (2024-2031). The main factors driving the market include strong demand for cost-efficient methods of production, demand for customized products, and technological advancements in 3D printing. Additive manufacturing is finding more applications in aerospace, healthcare, and automotive industries because additive manufacturing does not consume materials, thus saving them and prototyping faster. With the added focus on sustainability and without limitations on creating complex geometry, it opens a new way for further promotion of industry extension and innovation. Download a detailed overview: https://www.skyquestt.com/sample-request/additive-manufacturing-market...

LED Lighting and EV Charging Station Provider Orion to Present at LD Micro Investor Conference Tuesday, October 29th at 11:30am ET

Written by Customer Service on October 11, 2024. Posted in Public Companies.

LOS ANGELES and MANITOWOC, Wis., Oct. 11, 2024 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging station, and maintenance service solutions, announced it will be presenting at the LD Micro Main Event XVII at the Luxe Sunset Boulevard Hotel, on Tuesday, October 29th at 8:30 a.m. PT / 11:30 a.m. ET. CEO Mike Jenkins and CFO Per Brodin will also be available throughout the day on Tuesday and Wednesday morning for in-person investor meetings. Orion’s presentation will be open to all investors here. Management will review Orion’s business and growth outlook, followed by a Q&A session. Contact (registration@ldmicro.com) to register for the event and to schedule a meeting with Orion management. Orion Online Presentation AccessDate/Time: Tuesday,...

Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress

Written by Customer Service on October 11, 2024. Posted in Public Companies.

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that it expects to present two posters at the upcoming 19th Annual Cardiometabolic Health Congress (CMHC), taking place October 17-19, 2024, in Boston, MA. These posters highlight Tourmaline’s ongoing commitment to further characterizing inflammatory cardiovascular risk, as well as potential therapeutic mechanisms of IL-6 inhibition. Poster Presentations:Title: Utilization of High-Sensitivity C-Reactive Protein Testing in Primary and Secondary ASCVD PreventionAuthors: Emil deGoma, MD1; Yung Chyung, MD1; John Walsh, MD1; C. William Pike, MD2;...

Better Choice Company to Expand into Veterinary Medicine in 2025 Following the Acquisition of SRx Health

Written by Customer Service on October 11, 2024. Posted in Mergers And Acquisitions.

TAMPA, Fla., Oct. 11, 2024 (GLOBE NEWSWIRE) — Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet health and wellness company, today announced expansion plans into veterinary medicine in 2025 following the closing of the SRx Health acquisition. The new initiative, Better Pet Rx, will focus on providing care for your pets with love. “By leveraging the expertise of SRx Health’s management team, their pre-existing relationships with pharma, and their robust infrastructure, Better Choice can complement its Halo portfolio of premium and super-premium pet food products by expanding into veterinary medicine. Animal pharmaceuticals is a key area of growth within the pet care industry and will support Halo’s sustained momentum forward,” said Michael Young, Chairman of the Board. “This initiative aligns with our...

Global Tissue Diagnostics Market is Expected to Develop at a Moderate 6.6% CAGR through 2031 | SkyQuest Technology

Written by Customer Service on October 11, 2024. Posted in Mergers And Acquisitions.

Dive into the Tissue Diagnostics Market, projected to grow from USD 5.3 billion in 2023 to USD 9.42 billion by 2031, at a CAGR of 6.6%! Explore insights by product, technology, disease type, and more in our comprehensive forecast for 2024-2031. Westford, USA, Oct. 11, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Tissue Diagnostics Market will attain a value of USD 9.42 billion by 2031, with a CAGR of 6.6% over the forecast period (2024-2031). Advancements in diagnostic technologies and growing demand for early diagnosis around the world are estimated to bolster the tissue diagnostics market growth in the future. Surging prevalence of cancer and other chronic diseases is also expected to promote the demand for tissue diagnostics over the coming years. Browse in-depth TOC on “Tissue Diagnostics Market” Pages...

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Written by Customer Service on October 11, 2024. Posted in Public Companies.

MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 were presented at the Society for Neuroscience 2024 in Chicago, USA. The poster entitled, “Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of α-Synuclein Aggregation with Moderate Iron-binding Affinity,” demonstrates that the neuroprotective and mitochondrial protectant properties of ATH434 include reducing lipid damage in two distinct and disease-relevant neuronal injury models. Additional studies elucidate the inherent antioxidant properties and benefits of ATH434 in cellular energy...

Balchem Corporation Announces Quarterly Conference Call for Third Quarter Financial Results on October 25, 2024

Written by Customer Service on October 11, 2024. Posted in Public Companies.

MONTVALE, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) — Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, October 25, 2024, at 11:00 AM Eastern Time (ET) to review third quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Third quarter results will be published prior to the market opening on Friday, October 25, 2024. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341), five minutes prior to the scheduled start time of the conference call. The conference call will be available for replay three hours after the conclusion...

OTC Markets Group Welcomes Concord Acquisition Corp II to OTCQX

Written by Customer Service on October 11, 2024. Posted in Public Companies.

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Concord Acquisition Corp II (OTCQX: CNDA), a special purpose acquisition company, has qualified to trade on the OTCQX® Best Market. Concord Acquisition Corp II previously traded on NYSE American. Concord Acquisition Corp II begins trading today on OTCQX under the symbol “CNDA.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. Streamlined market requirements for OTCQX are designed to help companies lower the cost and complexity of being publicly traded, while providing transparent...

ATHA Energy Announces Option Agreements With Terra Uranium for Spire, Horizon, and Pasfield Projects

Written by Customer Service on October 11, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, Oct. 11, 2024 (GLOBE NEWSWIRE) — ATHA Energy Corp. (CSE: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA”) is pleased to announce, in furtherance to its news release from August 20th, 2024 , the Company and Terra Uranium Ltd. (ASX: T92) (“T92”) have executed a definitive option agreement for T92 to earn an option to acquire a 70% interest in ATHA’s Spire and Horizon properties (together, the “Spire Horizon Projects”) and a definitive option agreement for ATHA to earn an option to acquire up to a 60% interest in T92’s Pasfield Lake property (the “Pasfield Project”). SPIRE HORIZON OPTION In accordance with the terms of the Option Agreement ATHA shall grant T92 the sole and exclusive right and option to acquire up to a 70% interest in the Spire Horizon Projects (the “Spire Horizon Option”) in consideration for...

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Written by Customer Service on October 11, 2024. Posted in Public Companies.

– Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis –– Results support advancement of denifanstat into Phase 3 development – SAN MATEO, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that results from the Phase 2b FASCINATE-2 clinical trial of denifanstat versus placebo in biopsy-confirmed metabolic-dysfunction associated steatohepatitis (MASH) patients with stage 2 or stage 3 fibrosis (F2/F3) were published in The Lancet Gastroenterology & Hepatology. The publication, “Denifanstat...

Day: October 11, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals